Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

After subject screening, peripheral blood mononuclear cell #PBMC# donors matching half or more of the subject's HLA matching will undergo blood collection to prepare neoantigen cytotoxic T cells. Neoantigen cytotoxic T cells preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning. Chemotherapy preconditioning will be performed before neoantigen cytotoxic T cells transfusion.

Cyclophosphamide injection will be performed in -10 to -8d before neoantigen cytotoxic T cells transfusion

Decitabine Injection will be performed in -12 to -8d before neoantigen cytotoxic T cells transfusion

Liposome mitoxantrone will be performed in -9 to -8d before neoantigen cytotoxic T cells transfusion